Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 13;18(2):8.
doi: 10.1007/s11910-018-0814-x.

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

Suzanne Nielsen  1 , Rada Germanos  2 , Megan Weier  2   3 , John Pollard  4 , Louisa Degenhardt  2 , Wayne Hall  3 , Nicholas Buckley  4 , Michael Farrell  2
Affiliations

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

Suzanne Nielsen et al. Curr Neurol Neurosci Rep. .

Abstract

Purpose of review: Pharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high quality systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. We examined the outcomes of disability and disability progression, pain, spasticity, bladder function, tremor/ataxia, quality of life and adverse effects.

Recent findings: We identified 11 eligible systematic reviews providing data from 32 studies, including 10 moderate to high quality RCTs. Five reviews concluded that there was sufficient evidence that cannabinoids may be effective for symptoms of pain and/or spasticity in MS. Few reviews reported conclusions for other symptoms. Recent high quality reviews find cannabinoids may have modest effects in MS for pain or spasticity. Future research should include studies with non-cannabinoid comparators; this is an important gap in the evidence.

Keywords: Cannabinoid; Cannabis; Dronabinol; Multiple sclerosis; Nabiximols; Pain; Spasticity.

PubMed Disclaimer

References

    1. Drugs. 2013 Oct;73(15):1711-22 - PubMed
    1. J Clin Neurosci. 2014 Nov;21(11):1847-56 - PubMed
    1. Curr Opin Neurol. 2012 Feb;25 Suppl:S20-7 - PubMed
    1. BMJ. 2008 Apr 26;336(7650):924-6 - PubMed
    1. Lancet. 2008 Oct 25;372(9648):1502-17 - PubMed

Publication types

LinkOut - more resources